JP2012034699A - 汎用収集用保存液 - Google Patents
汎用収集用保存液 Download PDFInfo
- Publication number
- JP2012034699A JP2012034699A JP2011216080A JP2011216080A JP2012034699A JP 2012034699 A JP2012034699 A JP 2012034699A JP 2011216080 A JP2011216080 A JP 2011216080A JP 2011216080 A JP2011216080 A JP 2011216080A JP 2012034699 A JP2012034699 A JP 2012034699A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- preservation solution
- collection
- general
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims abstract description 46
- 238000004458 analytical method Methods 0.000 claims abstract description 30
- 230000002380 cytological effect Effects 0.000 claims abstract description 20
- 230000000877 morphologic effect Effects 0.000 claims abstract description 11
- 239000003761 preservation solution Substances 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 10
- 239000000834 fixative Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 239000011550 stock solution Substances 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 7
- 238000012742 biochemical analysis Methods 0.000 claims description 6
- 238000004445 quantitative analysis Methods 0.000 claims description 6
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- 230000003139 buffering effect Effects 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940122426 Nuclease inhibitor Drugs 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 2
- VXSGZEDHCOEWTR-UHFFFAOYSA-N chembl2008392 Chemical compound C1=CC=CC2=C(O)C(N=NC3=C4C=CC=C(C4=C(C=C3O)S(O)(=O)=O)[N+]([O-])=O)=CC=C21 VXSGZEDHCOEWTR-UHFFFAOYSA-N 0.000 claims description 2
- HLVXFWDLRHCZEI-UHFFFAOYSA-N chromotropic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HLVXFWDLRHCZEI-UHFFFAOYSA-N 0.000 claims description 2
- LJYRLGOJYKPILZ-UHFFFAOYSA-N murexide Chemical compound [NH4+].N1C(=O)NC(=O)C(N=C2C(NC(=O)NC2=O)=O)=C1[O-] LJYRLGOJYKPILZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000012511 carbohydrate analysis Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 47
- 201000010099 disease Diseases 0.000 abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 34
- 239000000523 sample Substances 0.000 abstract description 9
- 238000004321 preservation Methods 0.000 abstract description 6
- 238000007479 molecular analysis Methods 0.000 abstract description 4
- 239000013610 patient sample Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 183
- 239000000203 mixture Substances 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 25
- 210000002919 epithelial cell Anatomy 0.000 description 24
- 238000010186 staining Methods 0.000 description 23
- 238000003860 storage Methods 0.000 description 23
- 239000011521 glass Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 8
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 8
- 150000001298 alcohols Chemical class 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 6
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- KMQKYDWPAZMUDX-UHFFFAOYSA-M sodium;hydrogen sulfite;pentanedial Chemical compound [Na+].OS([O-])=O.O=CCCCC=O KMQKYDWPAZMUDX-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000000215 hyperchromic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005088 multinucleated cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YVGZCLMIVQGEPB-UHFFFAOYSA-N 1,5-dihydroxypentane-1,5-disulfonic acid Chemical group OS(=O)(=O)C(O)CCCC(O)S(O)(=O)=O YVGZCLMIVQGEPB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010068322 Oral papilloma Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- -1 RNasin Chemical class 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical class [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developing Agents For Electrophotography (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pens And Brushes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59857100A | 2000-06-21 | 2000-06-21 | |
| US09/598,571 | 2000-06-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504690A Division JP4879447B6 (ja) | 2000-06-21 | 2001-06-21 | 汎用収集用保存液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012034699A true JP2012034699A (ja) | 2012-02-23 |
| JP2012034699A5 JP2012034699A5 (enExample) | 2012-12-20 |
Family
ID=24396098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011216080A Pending JP2012034699A (ja) | 2000-06-21 | 2011-09-30 | 汎用収集用保存液 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7371518B2 (enExample) |
| EP (1) | EP1294853B1 (enExample) |
| JP (1) | JP2012034699A (enExample) |
| AT (1) | ATE466930T1 (enExample) |
| AU (3) | AU1548802A (enExample) |
| BR (1) | BR0112385A (enExample) |
| CA (1) | CA2414102A1 (enExample) |
| DE (1) | DE60142048D1 (enExample) |
| WO (1) | WO2001098542A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9814271A (pt) * | 1997-12-12 | 2001-03-20 | Digene Corp | Determinação de doenças relacionadas com o vìrus do papiloma humano |
| US20040115692A1 (en) * | 2000-04-03 | 2004-06-17 | Cytyc Corporation | Methods, compositions and apparatuses for detecting a target in a preservative solution |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| ES2784011T3 (es) | 2002-10-16 | 2020-09-21 | Streck Inc | Procedimiento y dispositivo para recoger y preservar las células para su análisis |
| EP1605244A1 (en) * | 2004-06-09 | 2005-12-14 | Boon, Mathilde Elisabeth | Fixative composition |
| WO2009066695A1 (ja) | 2007-11-20 | 2009-05-28 | Olympus Corporation | 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット |
| AU2009238247B2 (en) * | 2008-04-17 | 2014-12-11 | Qiagen Gaithersburg, Inc. | Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid |
| CN102027132A (zh) | 2008-05-12 | 2011-04-20 | 奥林巴斯株式会社 | 粪便处理方法及粪便处理容器 |
| TWI417389B (zh) | 2008-10-27 | 2013-12-01 | Qiagen Gaithersburg Inc | 於自動平台上之快速結果雜交捕捉法 |
| MX2011007624A (es) * | 2009-01-19 | 2011-10-12 | Hospices Civils Lyon | Metodos para determinar la susceptibilidad de contraer una infeccion nosocomial en el paciente y para establecer el pronostico de la evolucion del sindrome septico. |
| US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| EP3290530B1 (en) * | 2009-02-18 | 2020-09-02 | Streck Inc. | Preservation of cell-free nucleic acids |
| AU2010242867B2 (en) | 2009-05-01 | 2016-05-12 | Qiagen Gaithersburg, Inc. | A non-target amplification method for detection of RNA splice-forms in a sample |
| JP5826752B2 (ja) | 2009-09-14 | 2015-12-02 | キアジェン ゲイサーズバーグ インコーポレイテッド | 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法 |
| ES2615728T3 (es) * | 2010-01-29 | 2017-06-08 | Qiagen Gaithersburg, Inc. | Métodos y composiciones para una purificación y un análisis múltiple específico de secuencia de ácidos nucleicos |
| CA2787781A1 (en) | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Method of determining and confirming the presence of an hpv in a sample |
| US9422593B2 (en) | 2010-05-19 | 2016-08-23 | Qiagen Gaithresburg, Inc | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| US8980548B2 (en) | 2010-05-19 | 2015-03-17 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| EP2580348B1 (en) | 2010-06-14 | 2018-04-25 | Qiagen GmbH | Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples |
| CN107699618B (zh) | 2010-11-12 | 2021-08-20 | 茵赛德斯有限公司 | 非疾病诊断的确定宫颈上皮内瘤样(cin)细胞是否存在于来自受试者的标记液体宫颈细胞样本的方法和系统 |
| AU2012220575B2 (en) | 2011-02-24 | 2017-01-12 | Qiagen Gaithersburg, Inc. | Materials and methods for detection of HPV nucleic acid |
| WO2012151391A2 (en) | 2011-05-04 | 2012-11-08 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| EP4136972A1 (en) | 2013-07-24 | 2023-02-22 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
| EP3119197A1 (en) * | 2014-03-18 | 2017-01-25 | Qiagen GmbH | Stabilization and isolation of extracellular nucleic acids |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| US10365189B2 (en) * | 2015-05-07 | 2019-07-30 | Steven Wheeler | Histological specimen treatment |
| EP3329244B1 (en) | 2015-07-30 | 2022-10-05 | Qiagen GmbH | Method of preparing a frozen biological sample |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
| CN106929421B (zh) * | 2017-02-27 | 2020-12-01 | 中国计量科学研究院 | 定量保存微生物的冷冻干燥小球的制备方法 |
| US12378543B2 (en) | 2017-10-19 | 2025-08-05 | Streck Llc | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206965A (ja) * | 1982-02-04 | 1983-12-02 | ジエ−ムズ・エス・ハリソン | 生物学的系用保存剤および固定剤調剤 |
| JPS59222401A (ja) * | 1983-05-30 | 1984-12-14 | アルツ−ル・フアイフエル・ヴア−クウムテクニツク・ヴエツツラ−・ゲ−エムベ−ハ− | 生物学的標本の製造方法 |
| JPH0523179A (ja) * | 1991-05-01 | 1993-02-02 | Cytyc Corp | 細胞保存溶液 |
| US5370128A (en) * | 1993-12-02 | 1994-12-06 | Wainwright; Sharon R. | Pap brush and pap unit container systems |
| US5679333A (en) * | 1996-10-25 | 1997-10-21 | Dunphy; Brian William | Formaldehyde-free tissue preservative compositions |
| WO1998051693A1 (en) * | 1997-05-13 | 1998-11-19 | Genpoint As | Solid-phase nucleic acid isolation |
| WO1999031273A2 (en) * | 1997-12-12 | 1999-06-24 | Digene Corporation | Universal collection medium |
| US5976829A (en) * | 1994-04-22 | 1999-11-02 | Birnboim; Hyman C. | Dual purpose tissue fixative |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US129223A (en) * | 1872-07-16 | Improvement in privy-seats | ||
| US133972A (en) * | 1872-12-17 | Improvement in bolt-trimmers | ||
| US4578282A (en) * | 1982-02-04 | 1986-03-25 | Harrison James S | Composition for diagnostic reagents |
| US4465078A (en) | 1982-09-30 | 1984-08-14 | Medtest Corporation | Method for cell sampling in a body cavity |
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| EP0502994B1 (en) | 1989-12-01 | 1995-09-06 | Amoco Corporation | Detection of hpv transcripts |
| US5580970A (en) | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
| US5543294A (en) | 1991-07-19 | 1996-08-06 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria |
| IL106273A0 (en) | 1992-07-17 | 1993-11-15 | Res Dev Foundation | Rapid detection of biopolymers in stained specimens |
| US5357977A (en) * | 1993-04-23 | 1994-10-25 | St. Mary's Hospital And Medical Center, Inc. | Cytological sampling method and device |
-
2001
- 2001-06-21 AU AU1548802A patent/AU1548802A/xx active Pending
- 2001-06-21 WO PCT/US2001/041091 patent/WO2001098542A2/en not_active Ceased
- 2001-06-21 BR BR0112385-8A patent/BR0112385A/pt not_active IP Right Cessation
- 2001-06-21 AU AU2002215488A patent/AU2002215488B8/en not_active Ceased
- 2001-06-21 AT AT01984035T patent/ATE466930T1/de not_active IP Right Cessation
- 2001-06-21 CA CA002414102A patent/CA2414102A1/en not_active Abandoned
- 2001-06-21 EP EP01984035A patent/EP1294853B1/en not_active Expired - Lifetime
- 2001-06-21 DE DE60142048T patent/DE60142048D1/de not_active Expired - Lifetime
-
2003
- 2003-01-24 US US10/351,149 patent/US7371518B2/en not_active Expired - Fee Related
-
2007
- 2007-07-19 AU AU2007203372A patent/AU2007203372B2/en not_active Ceased
-
2011
- 2011-09-30 JP JP2011216080A patent/JP2012034699A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206965A (ja) * | 1982-02-04 | 1983-12-02 | ジエ−ムズ・エス・ハリソン | 生物学的系用保存剤および固定剤調剤 |
| JPS59222401A (ja) * | 1983-05-30 | 1984-12-14 | アルツ−ル・フアイフエル・ヴア−クウムテクニツク・ヴエツツラ−・ゲ−エムベ−ハ− | 生物学的標本の製造方法 |
| JPH0523179A (ja) * | 1991-05-01 | 1993-02-02 | Cytyc Corp | 細胞保存溶液 |
| US5370128A (en) * | 1993-12-02 | 1994-12-06 | Wainwright; Sharon R. | Pap brush and pap unit container systems |
| US5976829A (en) * | 1994-04-22 | 1999-11-02 | Birnboim; Hyman C. | Dual purpose tissue fixative |
| US5679333A (en) * | 1996-10-25 | 1997-10-21 | Dunphy; Brian William | Formaldehyde-free tissue preservative compositions |
| WO1998051693A1 (en) * | 1997-05-13 | 1998-11-19 | Genpoint As | Solid-phase nucleic acid isolation |
| WO1999031273A2 (en) * | 1997-12-12 | 1999-06-24 | Digene Corporation | Universal collection medium |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1294853A2 (en) | 2003-03-26 |
| JP2004500897A (ja) | 2004-01-15 |
| DE60142048D1 (de) | 2010-06-17 |
| AU2002215488B8 (en) | 2007-11-15 |
| WO2001098542A2 (en) | 2001-12-27 |
| CA2414102A1 (en) | 2001-12-27 |
| JP4879447B2 (ja) | 2012-02-22 |
| EP1294853B1 (en) | 2010-05-05 |
| AU2007203372B2 (en) | 2011-02-03 |
| US7371518B2 (en) | 2008-05-13 |
| ATE466930T1 (de) | 2010-05-15 |
| US20030119049A1 (en) | 2003-06-26 |
| AU1548802A (en) | 2002-01-02 |
| BR0112385A (pt) | 2003-06-17 |
| WO2001098542A3 (en) | 2002-06-20 |
| AU2007203372A1 (en) | 2007-08-09 |
| AU2002215488B2 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007203372B2 (en) | Universal collection medium | |
| AU748022B2 (en) | Universal collection medium | |
| AU2002215488A1 (en) | Universal collection medium | |
| Ambros et al. | Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines | |
| US6337189B1 (en) | Fixative system, method and composition for biological testing | |
| US10314301B2 (en) | Method of preserving cells | |
| JP2019502386A (ja) | グアニジウムチオシアネートを含むハイブリダイゼーション緩衝液 | |
| CN118599961A (zh) | 尿液稳定化 | |
| JP4879447B6 (ja) | 汎用収集用保存液 | |
| Abati et al. | If cells could talk: the application of new techniques to cytopathology | |
| JP2004500897A5 (enExample) | ||
| US7422858B2 (en) | Apparatus and method for separating viral particles from cells | |
| JP2007526743A (ja) | クロマチン分析を利用して細胞の侵襲可能性を評価するための方法 | |
| Teng et al. | A new method for real-time evaluation of pepsin digestion of paraffin-embedded tissue sections, prior to fluorescence in situ hybridisation | |
| He et al. | Cytology Techniques | |
| Zabka et al. | Diagnostic techniques in aquatic animal medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121029 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130912 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131210 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131213 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140508 |